TransMedics to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
TransMedics Group, Inc. (Nasdaq: TMDX) will announce its fourth quarter and full year 2021 financial results on February 23, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransMedics Group, Inc. (Nasdaq: TMDX) will announce its fourth quarter and full year 2021 financial results on February 23, 2022, after market close. A conference call to discuss the results will take place at 4:30 p.m. ET. The company specializes in portable extracorporeal warm perfusion for organ transplants, aiming to enhance organ availability for patients with end-stage conditions. Interested investors can access the call via phone or through a live webcast available on their website.
Positive
- Company is focused on improving organ transplant therapy for critical patients.
- TransMedics is recognized as a leader in organ preservation and assessment.
Negative
- None.
Details
News Market Reaction – TMDX
The recorded move for TMDX in the trading session of this news was -2.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANDOVER, Mass., Feb. 9, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23, 2022. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Investors interested in listening to the conference call may do so by dialing (833) 378-1026 for domestic callers or (236) 712-2500 for international callers, followed by Conference ID: 9789660. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-fourth-quarter-and-full-year-2021-financial-results-on-february-23-2022-301476600.html
SOURCE TransMedics Group, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.